Synapticure Inc.
Kenilworth, IL
- UEI
- G9QUJCDRVYB7
- CAGE
- 8PUS5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 618 Melrose Ave, Kenilworth, IL 60043, USA
- Website
- synapticure.com
- Founded
- 2019
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Trustees Of Columbia University In The City Of New York | U01NS136023 | $1,470,489 | |
| The Trustees Of Columbia University In The City Of New York | U01NS136023 | $1,470,478 | |
| The Trustees Of Columbia University In The City Of New York | U01NS136023 | $1,470,489 |
Similar vendors
About the company
Synapticure Inc. is a for-profit corporate entity registered in SAM.gov since August 2020, located in Kenilworth, Illinois. The company specializes in developing advanced neurological research platforms, specifically focusing on creating innovative 3D in vitro models for neurodegenerative disease research. Their primary technological focus appears to be on developing sophisticated brain organoid systems that can model complex cellular interactions, particularly for conditions like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). These platforms are designed to provide high-fidelity modeling and screening of disease-specific proteinopathies and biomarkers, addressing critical gaps in current neurological research methodologies.
Through federal grant awards, primarily from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, Synapticure has been developing patient-derived 3D platforms for modeling neurodegenerative diseases. Their grants, including R44NS143521, R43NS134458, and R44NS124457, focus on creating advanced brain organoid systems like Cortical Brain Spheroids (CBS) and Massembloids that can recapitulate key disease features of ALS and FTD. The company has been awarded substantial funding, including a $2.5 million grant to develop 3D in vitro models for frontotemporal dementia. Additionally, they have engaged in a sub-award with Columbia University for an expanded access protocol for ALS patients, demonstrating their commitment to translational research. Their work involves generating complex cellular models using induced pluripotent stem cells, evaluating disease-specific markers like TDP-43 proteinopathy, and developing platforms for potential therapeutic screening and biomarker identification.
Quick answers
Is Synapticure Inc. registered in SAM.gov?
Yes. Synapticure Inc.'s SAM.gov registration is active through October 8, 2027.
What is Synapticure Inc.'s most recent federal award?
Synapticure Inc.'s most recent federal grant award is 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development (R44NS143521), from National Institute of Neurological Disorders and Stroke (NIH), on May 9, 2025.
On GovTribe
See Synapticure Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors